Authors: Tetsuji Yamaguchi Yasumasa Takii Satoshi Maruyama
Publish Date: 2013/08/23
Volume: 44, Issue: 8, Pages: 1529-1535
Abstract
Recently the serum p53 antibody Sp53Ab has been used widely in clinical practice as a tumor marker for colorectal cancer CRC However no largescale studies have examined the usefulness of serial measurements of Sp53Ab or have established the relationship of this parameter with the clinicopathological factors of CRCThe Sp53Ab positivity rate was 241 and was significantly higher in Stage III–IV than in Stage 0–II cases However no relationship was seen with the serum carcinoembryonic antigen CEA or carbohydrate antigen 199 CA199 levels The addition of the Sp53Ab assay to the CEA and CA199 measurements increased the overall diagnostic sensitivity to 509 CEA and/or CA199 373 In patients who had undergone complete resection Sp53Ab positivity was associated with a decrease in the relapsefree survival p = 0012 but it was not independent prognostic indicator Sp53Ab positivity had no influence on the cancerspecific survival
Keywords: